BNR is navigating a peculiar crossroads: it just printed a better-than-feared Q1 while the lending market simultaneously flashes its sharpest warning signals in months.
The most striking development this week is in the borrow market. Cost to borrow more than quadrupled over 30 days — running at 8.18% as of May 12, up from around 1.4% in early April. That move is even more compressed looking at just the last week: CTB roughly doubled in five sessions. This is not a gentle drift higher. The spike arrived just as Q1 earnings landed on May 13, with availability tightening sharply heading into the print. For most of April, borrowing conditions were loose and costs benign. The sudden reversal signals that new short demand entered the stock in a hurry.
Short interest underlines the urgency. The estimated SI as a percentage of free float climbed from roughly 9.9% in late April to 12.3% by May 12 — a move of more than two percentage points in under three weeks. That is a meaningful build by any measure in a mid-cap distributor. At the same time, the ORTEX short score has been running above 80 for most of the past two weeks, touching 83.2 on May 11 before easing slightly to 78.8 on May 12 — still firmly elevated. Availability, which had been comfortable through most of April, tightened materially into the earnings date, reinforcing the impression of a concerted positioning move rather than passive drift.
The earnings themselves complicate the short narrative. Brenntag Q1 revenue came in at €3.66 billion against €4.07 billion a year earlier — a year-on-year decline — but core profit beat market expectations. CEO Jens Birgersson attributed the difficult comparables to a slow January and February before the outbreak of conflict in the Middle East around February 28 disrupted chemical supply routes through the Strait of Hormuz. The company said it pivoted within days, implementing pricing surcharges and securing supply, and entered March in volume growth territory. Full-year guidance was confirmed. The stock closed at €62.02, down 1.3% on the day and off about 1.1% for the week — unremarkable given the noise, and up 6% from a month ago.
The Street's positioning reflects genuine uncertainty about the durability of the Q1 boost. Analyst consensus sits at hold, with three buys against eight holds and no sell ratings. That skew — no outright bears, but a cautious majority — matches the valuation picture: the P/E at 16x has expanded roughly 4% over 30 days, and EV/EBITDA at 8.7x has actually compressed marginally over the same period. The EPS momentum score ranks in the 68th percentile on a 30-day view, but slips to the 38th percentile over 90 days, suggesting the near-term estimate revisions are stronger than the structural trend. The analyst recommendation differential factor ranks in the 98th percentile — an unusually wide gap between current consensus and historical positioning — which may partly explain why short sellers see an opportunity even after a beat.
On the ownership side, the most notable institutional move is Wellington Management, which added roughly 2.9 million shares in the quarter to March 31, bringing its stake to 5%. Goldman Sachs also appeared as a new holder, disclosing 1.6 million shares as of mid-March. On the insider side, activity over the past 90 days has been modest — net buying of roughly 950 shares valued at around $55,000 — largely supervisory board members making small purchases. CEO Birgersson made a more meaningful purchase of 10,000 shares at around €49.90 back in September 2025, well below the current price, which at least signals he was comfortable at lower levels.
The Q4 2025 print in March is the only recent earnings event with a price reaction on record: the stock rose 5.4% on the day and added another 2.6% over the following week. Q1 landed today with a much quieter tape response. The next scheduled reporting date is August 12 for H1 results; the data snapshot flags May 20 as a near-term event date — likely related to a Capital Markets Day or an investor update Birgersson referenced on the call, which is formally scheduled for November 12. What to watch between now and August is whether the Iran-related pricing tailwind holds into Q2, whether the borrow cost spike eases as the earnings overhang clears, or whether the short build deepens — any of those three outcomes will tell a very different story about where this stock goes next.
See the live data behind this article on ORTEX.
Open BNR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
